Armistice Capital’s Biofrontera BFRI Stock Holding History

Armistice Capital’s Portfolio BFRI Stock Details BFRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-38,182	Closed	-$1.42K	–	202
2022 Q2	$1.42K	Buy	+38,182	New	+$2.32M	0.02%	121

Other funds holding BFRI

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Armistice Capital's BFRI Position: Q3 2022 in Review

Armistice Capital sold out of Biofrontera (BFRI) in Q3 2022, closing a stake of 38,182 shares — an estimated $1.42K sold.

Armistice Capital first reported a position in BFRI in Q2 2022 and held it in 1 quarter. The position peaked at $1.42K in Q2 2022. 16 funds tracked by Wall St. Rank hold BFRI as of Q3 2022.

Armistice Capital reported no remaining Biofrontera position as of Q3 2022 after selling out during the quarter.
Armistice Capital sold 38,182 Biofrontera shares in Q3 2022, an estimated $1.42K.
Armistice Capital first reported a position in Biofrontera in Q2 2022 and held it in 1 quarter.
Armistice Capital's Biofrontera position peaked at $1.42K in Q2 2022.
16 funds tracked by Wall St. Rank held Biofrontera as of Q3 2022.

Based on Armistice Capital's 13F filing for Q3 2022, filed 14 Nov 2022.